Targeting MAPK in recurrent, low-grade serous ovarian cancer. Blagden SP. Lancet 2022;399:499-501.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Blagden SP. Targeting MAPK in recurrent, low-grade serous ovarian cancer. Lancet 2022;399:499-501.
PMID: 35123677